From model to mechanism: Lessons of mice and men in the discovery of protein biologicals for the treatment of inflammatory bowel disease

Expert Opinion on Drug Discovery

Volumn 1, Issue 1, 2006, Pages 69-83

  Bilsborough, Janine ^a   Viney, Joanne L ^b  

^a ZYMOGENETICS INC   (United States)

^b Department of Inflammation ^*  (United States)

Author keywords

animal models; Crohns disease; cytokines; inflammatory bowel disease; ulcerative colitis

Indexed keywords

EID: 74549134169     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.1.1.69     Document Type: Review

References (128)

1. MACDONALD TT, MONTELEONE G, PENDER SL: Recent developments in the immunology of inflammatory bowel disease. Scand. J. Immunol. (2000) 51(1):2-9. (Pubitemid 30074296)
2. NIELSEN OH, KIRMAN I, RUDIGER N et al.: Upregulation of interleukin-12 and -17 in active inflammatory bowel disease. Increased expression of interleukin 17 in inflammatory bowel disease. Scand. J. Gastroenterol. (2003) 38(2):180-185. (Pubitemid 36349930)
3. FUJINO S, ANDOH A, BAMBA S et al.: Increased expression of interleukin 17 in inflammatory bowel disease. Gut (2003) 52(1):65-70. (Pubitemid 36020767)
4. REUTER B,KPIZARRO TT: Commentary: the role of the IL-18 system and other members of the IL-1R/TLR superfamily in innate mucosal immunity and the pathogenesis of inflammatory bowel disease: friend or foe? Eur. J. Immunol. (2004) 34(9):2347-2355.
5. MONTELEONE G, MONTELEONE I, FINA D et al.: Interleukin-21 enhances T-helper cell type I signaling and interferon-ã production in Crohns disease. Gastroenterology (2005) 128(3):687-694. (Pubitemid 40585371)
6. SCHMIDT C, GIESE T, LUDWIG B et al.: Expression of interleukin-12-related cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohns disease but not in ulcerative colitis. Inflamm. Bowel Dis. (2005) 11(1):16-23. (Pubitemid 40340252)
7. FUSS IJ, NEURATH M, BOIRIVANT M et al.: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohns disease LP cells manifest increased secretion of IFN-ã, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. (1996) 157(3):1261-1270. (Pubitemid 126449643)
8. JURJUS AR, KHOURY NN, REIMUND JM: Animal models of inflammatory bowel disease. J. Pharmacol. Toxicol. Methods (2004) 50(2):81-92. (Pubitemid 39286320)
9. NEURATH MF: Animal models of inflammatory bowel diseases. Ernst Schering Res Found Workshop. (2005) 50:119-132.
10. WIRTZ S, NEURATH MF: Animal models of intestinal inflammation: new insights into the molecular pathogenesis and immunotherapy of inflammatory bowel disease. Int. J. Colorectal Dis. (2000) 15(3):144-160.
11. ABERRA FN, LICHTENSTEIN GR: Review article: monitoring of immunomodulators in inflammatory bowel disease. Aliment. Pharmacol. Ther. (2005) 21(4):307-319. (Pubitemid 40313935)
12. LI M, CHE SH: IL-10 and its related cytokines for treatment of inflammatory bowel disease. World J. Gastroenterol. (2004) 10(5):620-625.
13. KUHN R, LOHLER J, RENNICK D, RAJEWSKY K, MULLER W: Interleukin-10- deficient mice develop chronic enterocolitis. Cell (1993) 75(2):263-274. (Pubitemid 23320290)
14. TOMOYOSE M, MITSUYAMA K, ISHIDA H, TOYONAG A, ATANIKAWA K: Role of interleukin-10 in a murine model of dextran sulfate sodium-induced colitis. Scand. J. Gastroenterol. (1998) 33(4):435-440. (Pubitemid 28212558)
15. RENNICK DM, FORT MM: Lessons from genetically engineered animal models. XII. IL-10-deficient IL-10-/- mice and intestinal inflammation. Am. J. Physiol. Gastrointest. Liver Physiol. (2000) 278(6):G829-G833. (Pubitemid 30439159)
16. VAN DEVENTER SJ, ELSON COFEDORAK RN: Multiple doses of intravenous interleukin 10 in steroid-refractory Crohns disease. Crohns Disease Study Group. Gastroenterology (1997) 113(2):383-389. (Pubitemid 27351761)
17. SCHREIBER S, FEDORAK RN, NIELSEN OH et al.: Safety and efficacy of recombinant human interleukin 10 in chronic active Crohns disease. Crohns Disease IL-10 Cooperative Study Group. Gastroenterology (2000) 119(6):1461-1472. (Pubitemid 32198671)
18. FEDORAK RN, GANGL A, ELSON CO, et al.: Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohns disease. The Interleukin 10 Inflammatory Bowel Disease Cooperative Study Group. Gastroenterology (2000) 119(6):1473-1482. (Pubitemid 32198672)
19. TILG H, VAN MONTFRANS C, VAN DEN ENDE A et al.: Treatment of Crohns disease with recombinant human interleukin 10 induces the proinflammatory cytokine interferon ã. Gut (2002) 50(2):191-195. (Pubitemid 34087930)
20. MADSEN K: Combining T cells and IL-10: a new therapy for Crohns disease? Gastroenterology (2002) 123(6):2140-2144. (Pubitemid 35408335)
21. KEITH JC Jr, ALBERT L, SONIS ST, PFEIFFER CJ, SCHAUB RG: IL-11, a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells (1994) 12(Suppl 1):79-89 (Discussion 89-90).
22. QIU BS, PFEIFFER CJ, KEITH JC Jr: Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig. Dis. Sci. (1996) 41(8):1625-1630. (Pubitemid 26285750)
23. PETERSON RL, WANG L, ALBERT L, KEITH JC Jr, DORNER AJ: Molecular effects of recombinant human interleukin-11 in the HLA-B27 rat model of inflammatory bowel disease. Lab. Invest. (1998) 78(12):1503-1512. (Pubitemid 29022226)
24. SONIS ST, PETERSON RL, EDWARDS LJ et al.: Defining mechanisms of action of interleukin-11 on the progression of radiation-induced oral mucositis in hamsters. Oral Oncol. (2000) 36(4):373-381. (Pubitemid 30427259)
25. TREPICCHIO WL, BOZZA M, PEDNEAULT G, DORNER AJ: Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J. Immunol. (1996) 157(8):3627-3634. (Pubitemid 126449177)
26. ORAZI A, DU X, YANG Z, KASHAI M, WILLIAMS DA: Interleukin-11 prevents apoptosis and accelerates recovery of small intestinal mucosa in mice treated with combined chemotherapy and radiation. Lab. Invest. (1996) 75(1):33-42. (Pubitemid 26250271)
27. KLEIN W, TROMM A, GRIGA T et al.: A polymorphism in the IL11 gene is associated with ulcerative colitis. Genes Immun. (2002) 3(8):494-496. (Pubitemid 41656534)
28. SANDS BE, BANK S, SNINSKY CA et al.: Preliminary evaluation of safety and activity of recombinant human interleukin 11 in patients with active Crohns disease. Gastroenterology (1999) 117(1):58-64. (Pubitemid 29297620)
29. SANDS BE, WINSTON BD, SALZBERG B et al.: Randomized, controlled trial of recombinant human interleukin-11 in patients with active Crohns disease. Aliment. Pharmacol. Ther. (2002) 16(3):399-406. (Pubitemid 34214518)
30. MAKRAUER FL, BURAKOFF R: Biologic and novel therapy of the inflammatory bowel diseases. Curr. Med. Chem. - Anti-Inflamm. Anti-Allergy Agents. (2005) 4(3):319-331. (Pubitemid 40867270)
31. HASSAN C, ZULLO A, CAMPO S, MAMORINI S: New insights into the biological therapy of Crohns disease. Expert Opin. Ther. Patents. (2005) 15(4):409-419. (Pubitemid 40613896)
32. WILK JN, VINEY JL: GM-CSF treatment for Crohns disease: a stimulating new therapy? Curr. Opin. Investig. Drugs (2002) 3(9):1291-1296. (Pubitemid 36266748)
33. BALDWIN GC: The biology of granulocyte-macrophage colony-stimulating factor: effects on hematopoietic and nonhematopoietic cells. Dev. Biol. (1992) 151(2):352-367.
34. KORZENIK JR, DIECKGRAEFE BK, VALENTINE JF, HAUSMAN DF, GILBERT MJ: Sargramostim for active Crohns disease. N. Engl. J. Med. (2005) 352(21):2193-2201.
35. RUTHER U, NUNNENSIEK C, MULLER HA, BADER H, MAY U, JIPP P: Interferon á (IFN á2a) therapy for herpes virus-associated inflammatory bowel disease (ulcerative colitis and Crohns disease). Hepatogastroenterology (1998) 45(21):691-699. (Pubitemid 28321042)
36. MADSEN SM, SCHLICHTING P, DAVIDSEN B et al.: An open-labeled, randomized study comparing systemic interferon-á-2A and prednisolone enemas in the treatment of left-sided ulcerative colitis. Am. J. Gastroenterol. (2001) 96(6):1807-1815.
37. NIKOLAUS S, RUTGEERTS P, FEDORAK R et al.: Interferon â-1a in ulcerative colitis: a placebo controlled, randomised, dose escalating study. Gut (2003) 52(9):1286-1290. (Pubitemid 37026460)
38. KATAKURA K, LEE J, RACHMILEWITZ D, LI G, ECKMANN L, RAZ E: Toll-like receptor 9-induced type I IFN protects mice from experimental colitis. J. Clin. Invest. (2005) 115(3):695-702. (Pubitemid 40322244)
39. AMAN MJ, TRETTER T, EISENBEIS I, et al.: Interferon-á stimulates production of interleukin-10 in activated CD4+ T cells and monocytes. Blood (1996) 87(11):4731-4736. (Pubitemid 26162373)
40. BILSBOROUGH J, GEORGE TC, NORMENT A, VINEY JL: Mucosal CD8á+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology (2003) 108(4):481-492. (Pubitemid 36469686)
41. LEVINGS MK, SANGREGORIO R, GALBIATI F: IFN-á and IL-10 induce the differentiation of human type 1 T regulatory cells. J. Immunol. (2001) 166(9):5530-5539. (Pubitemid 32374175)
42. PESTKA S, KRAUSE CD, WALTER MR: Interferons, interferon-like cytokines, and their receptors. Immunol. Rev. (2004) 202:8-32. (Pubitemid 39576902)
43. MANNON PJ, FUSS IJ, MAYER L et al.: Anti-interleukin-12 antibody for active Crohns disease. N. Engl. J. Med. (2004) 351(20):2069-2079. (Pubitemid 39482500)
44. LIU Z, GEBOES K, HEREMANS et al.: Role of interleukin-12 in the induction of mucosal inflammation and abrogation of regulatory T cell function in chronic experimental colitis. Eur. J. Immunol. (2001) 31(5):1550-1560. (Pubitemid 32454704)
45. STALLMACH A, MARTH T, WEISS B et al.: An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohns disease and experimental colitis in vivo. Gut (2004) 53(3):339-345. (Pubitemid 38241326)
46. LING P, GATELY MK, GUBLER U et al.: Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J. Immunol. (1995) 154(1):116-127.
47. PFLANZ S, TIMANS JC, CHEUNG J, et al.: IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4+ T cells. Immunity (2002) 16(6):779-790. (Pubitemid 34786477)
48. BREGENHOLT S, BRIMNES J, NISSEN MH, CLAESSON MH: In vitro activated CD4+ T cells from interferon-ã (IFN-ã)-deficient mice induce intestinal inflammation in immunodeficient hosts. Clin. Exp. Immunol. (1999) 118(2):228-234. (Pubitemid 29519252)
49. DOHI T, FUJIHASHI K, RENNERT PD, IWATANI K, KIYONO H, MCGHEE JR: Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J. Exp. Med. (1999) 189(8):1169-1180.
50. CAMOGLIO L, TE VELDE AA, DE BOER A, TEN KATE FJ, KOPF M, VAN DEVENTER SJ: Hapten-induced colitis associated with maintained Th1 and inflammatory responses in IFN-ã receptor-deficient mice. Eur. J. Immunol. (2000) 30(5):1486-1495. (Pubitemid 30311980)
51. DUMONT FJ: Fontolizumab Protein Design Labs. Curr Opin Investig Drugs. (2005) 6(5):537-544. (Pubitemid 40613977)
52. PAPADAKIS K, ATARGAN SR: Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology (2000) 119(4):1148-1157.
53. NEURATH MF, FUSS I, PASPARAKIS M et al.: Predominant pathogenic role of tumor necrosis factor in experimental colitis in mice. Eur. J. Immunol. (1997) 27(7):1743-1750. (Pubitemid 27302858)
54. MARINI M, BAMIAS G, RIVERA-NIEVES J et al.: TNF-á neutralization ameliorates the severity of murine Crohns-like ileitis by abrogation of intestinal epithelial cell apoptosis. Proc. Natl. Acad. Sci. USA (2003) 100(14):8366-8371. (Pubitemid 36842551)
55. KONTOYIANNIS D, PASPARAKIS M, PIZARRO TT, COMINELLI F, KOLLIAS G: Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity. (1999) 10(3):387-398. (Pubitemid 29165293)
56. RUTGEERTS P, VAN ASSCHE G, VERMEIRE S: Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology (2004) 126(6):1593-1610. (Pubitemid 38649876)
57. BAERT F, NOMAN M, VERMEIRE S et al.: Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N. Engl. J. Med. (2003) 348(7):601-608. (Pubitemid 36204954)
58. SPAHN TW, KUCHARZIK T: Modulating the intestinal immune system: the role of lymphotoxin and GALT organs. Gut (2004) 53(3):456-465. (Pubitemid 38241347)
59. MACKAY F, BROWNING JL, LAWTON P et al.: Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology (1998) 115(6):1464-1475. (Pubitemid 28545997)
60. DOHI T, RENNERT PD, FUJIHASHI K, et al.: Elimination of colonic patches with lymphotoxin â receptor-Ig prevents TH2 cell-type colitis. J. Immunol. (2001) 167(5):2781-2790. (Pubitemid 32768910)
61. STOPFER P, OBERMEIER F, DUNGER N et al.: Blocking lymphotoxin-â receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis. Clin. Exp. Immunol. (2004) 136(1):21-29. (Pubitemid 38437761)
62. CARTER MJ, JONES S, CAMP NJ et al.: Functional correlates of the interleukin-1 receptor antagonist gene polymorphism in the colonic mucosa in ulcerative colitis. Genes Immun. (2004) 5(1):8-15. (Pubitemid 38967624)
63. LUDWICZEK O, VANNIER E, BORGGRAEFE I et al.: Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease. Clin. Exp. Immunol. (2004) 138(2):323-329. (Pubitemid 39472451)
64. COMINELLI F, PIZARRO TT: Interleukin-1 and interleukin-1 receptor antagonist in inflammatory bowel disease. Aliment. Pharmacol. Ther. (1996) 10(Suppl. 2):49-53 (Discussion 54). (Pubitemid 26341295)
65. THOMAS TK, WILL PC, SRIVASTAVA A et al.: Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model. Agents Actions. (1991) 34(1-2):187-190.
66. ROGLER G, ANDUS T: Cytokines in inflammatory bowel disease. World J. Surg. (1998) 22(4):382-389. (Pubitemid 28113526)
67. RICCI S, MACCHIA G, RUGGIERO P et al.: In vivo mucosal delivery of bioactive human interleukin 1 receptor antagonist produced by Streptococcus gordonii cytokines in inflammatory bowel disease. BMC Biotechnol. (2003) 3(4):15.
68. KANAI T, WATANABE M, OKAZAWA A et al.: Interleukin 18 is a potent proliferative factor for intestinal mucosal lymphocytes in Crohns disease. Gastroenterology (2000) 119(6):1514-1523. (Pubitemid 32198677)
69. CHANG JT, SEGAL BM, NAKANISHI K, OKAMURA H, SHEVACH EM: The costimulatory effect of IL-18 on the induction of antigen-specific IFN-ã production by resting T cells is IL-12 dependent and is mediated by up-regulation of the IL-12 receptor â2 subunit. Eur. J. Immunol. (2000) 30(4):1113-1119. (Pubitemid 30216228)
70. HOSHINO T, WILTROUT RH, YOUNG HA: IL-18 is a potent coinducer of IL-13 in NK and T cells: a new potential role for IL-18 in modulating the immune response. J. Immunol. (1999) 162(9):5070-5077. (Pubitemid 29307106)
71. CAMOGLIO L, JUFFERMANS NP, PEPPELENBOSCH M et al.: Contrasting roles of IL-12p 40 and IL-12p 35 in the development of hapten-induced colitis. Eur. J. Immunol. (2002) 32(1):261-269. (Pubitemid 34092843)
72. KANAI T, WATANABE M, OKAZAWA A et al.: Macrophage-derived IL-18-mediated intestinal inflammation in the murine model of Crohns disease. Gastroenterology (2001) 121(4):875-888. (Pubitemid 32959397)
73. TAKAGI H, KANAI T, OKAZAWA A et al.: Contrasting action of IL-12 and IL-18 in the development of dextran sodium sulphate colitis in mice. Scand. J. Gastroenterol. (2003) 38(8):837-844. (Pubitemid 37011577)
74. CREED TJ, NORMAN MR, PROBERT CS et al.: Basiliximab (anti-CD25) in combination with steroids may be an effective new treatment for steroid-resistant ulcerative colitis. Aliment. Pharmacol. Ther. (2003) 18(1):65-75. (Pubitemid 36897982)
75. VAN ASSCHE G, DALLE I, NOMAN M et al.: A pilot study on the use of the humanized anti-interleukin-2 receptor antibody daclizumab in active ulcerative colitis. Am. J. Gastroenterol. (2003) 98(2):369-376. (Pubitemid 36232388)
76. SADLACK B, LOHLER J, SCHORLE H et al.: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur. J. Immunol. (1995) 25(11):3053-3059.
77. MAKITA S, KANAI T, OSHIMA S, URAUSHIHARA K et al.: CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J. Immunol. (2004) 173(5):3119-3130. (Pubitemid 39142018)
78. MALOY KJ, ANTONELLI LR, LEFEVRE M: Cure of innate intestinal immune pathology by CD4+CD25+ regulatory T cells. Immunol. Lett. (2005) 97(2):189-192. (Pubitemid 40326950)
79. VELTKAMP C, SARTOR RB, GIESE T et al.: Regulatory CD4+CD25+ cells reverse imbalances in the T cell pool of bone marrow transplanted TGå26 mice leading to the prevention of colitis. Gut (2005) 54(2):207-214. (Pubitemid 40139235)
80. ITO H: Novel therapy for Crohns disease targeting IL-6 signalling. Expert Opin. Ther. Targets (2004) 8(4):287-294. (Pubitemid 39117694)
81. ITO H: Treatment of Crohns disease with anti-IL-6 receptor antibody. J. Gastroenterol. (2005) 40(Suppl 16)32-34.
82. YAMAMOTO M, YOSHIZAKI K, KISHIMOTO T, ITO H: IL-6 is required for the development of Th1 cell-mediated murine colitis. J. Immunol. (2000) 164(9):4878-4882. (Pubitemid 30238092)
83. MUDTER J, WIRTZ S, GALLE PR, NEURATH MF: A new model of chronic colitis in SCID mice induced by adoptive transfer of CD62L+ CD4+ T cells: insights into the regulatory role of interleukin-6 on apoptosis. Pathobiology (2002-2003) 70(3):170-176. (Pubitemid 36184451)
84. ITO H: IL-6 and Crohns disease. Curr. Drug Targets Inflamm. Allergy (2003) 2(2):125-130.
85. TAUB DD, LLOYD AR, CONLON K et al.: Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells. J. Exp. Med. (1993) 177(6):1809-1814. (Pubitemid 23146150)
86. SCHEERENS H, HESSEL E, DE WAAL-MALEFYT R, LEACH M, WRENNICK D: Characterization of chemokines and chemokine receptors in two murine models of inflammatory bowel disease: IL-10-/- mice and Rag-2-/- mice reconstituted with CD4+CD45RBhigh T cells. Eur. J. Immunol. (2001) 31(5):1465-1474. (Pubitemid 32454694)
87. QIN S, ROTTMAN JB, MYERS P, KASSAM N, WEINBLATT M, LOETSCHER M et al.: The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J. Clin. Invest. (1998) 101(4):746-754. (Pubitemid 28096070)
88. PAPADAKIS KA, PREHN J, ZHU D et al.: Expression and regulation of the chemokine receptor CXCR3 on lymphocytes from normal and inflammatory bowel disease mucosa. Inflamm. Bowel Dis. (2004) 10(6):778-788. (Pubitemid 39545224)
89. SINGH UP, SINGH S, TAUB DD, LILLARD JW Jr: Inhibition of IFN-ã-inducible protein-10 abrogates colitis in IL-10-/- mice. J. Immunol. (2003) 171(3):1401-1406. (Pubitemid 36900073)
90. UGUCCIONI M, GIONCHETTI P, ROBBIANI DF et al.: Increased expression of IP-10, IL-8, MCP-1, and MCP-3 in ulcerative colitis. Am. J. Pathol. (1999) 155(2):331-336. (Pubitemid 29370382)
91. SPRINGER T, AWANG JH: The three-dimensional structure of integrins and their ligands, and conformational regulation of cell adhesion. Adv. Protein Chem. (2004) 68:29-63 (Pubitemid 41184478)
92. HAMANN A, ANDREW DP, JABLONSKI-WESTRICH D, HOLZMANN BBUTCHER EC: Role of á 4-integrins in lymphocyte homing to mucosal tissues in vivo. J. Immunol. (1994) 152(7):3282-3293.
93. BRISKIN M, WINSOR-HINES D, SHYJAN A et al.: Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am. J. Pathol. (1997) 151(1):97-110. (Pubitemid 27283962)
94. ARIHIRO S, OHTANI H, SUZUKI M et al.: Differential expression of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) in ulcerative colitis and Crohns disease. Pathol. Int. (2002) 52(5-6):367-374. (Pubitemid 34748219)
95. KATO S, HOKARI R, MATSUZAKI K et al.: Amelioration of murine experimental colitis by inhibition of mucosal addressin cell adhesion molecule-1. J. Pharmacol. Exp. Ther. (2000) 295(1):183-189.
96. GORDON FH, LAI CW, HAMILTON MI et al.: A randomized placebo-controlled trial of a humanized monoclonal antibody to á integrin in active Crohns disease. Gastroenterology (2001) 121(2):268-274. (Pubitemid 32729374)
97. GHOSH S, GOLDIN E, GORDON FH et al.: Natalizumab for active Crohns disease. N. Engl. J. Med. (2003) 348(1):24-32.
98. VAN ASSCHE G, VAN RANST M, SCIOT R et al.: Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohns disease. N. Engl. J. Med. (2005) 353(4):362-368. (Pubitemid 41132340)
99. FEAGAN B, MCDONALD J,GREENBERG G: A randomized controlled trial of a humanized á4â7 antibody in ulcerative colitis (UC) Gastroenterology (2000) 118:A874 (Abstract).
100. FEAGAN BG, GREENBERG GR, WILD G et al.: Treatment of ulcerative colitis with a humanized antibody to the á4â7 integrin. N. Engl. J. Med. (2005) 352(24):2499-2507. (Pubitemid 41007865)
101. VAINER B: Intercellular adhesion molecule-1 (ICAM-1) in ulcerative colitis: presence, visualization, and significance. Inflamm. Res. (2005) 54(8):313-327. (Pubitemid 41291655)
102. SALMI M, JALKANEN S: Lymphocyte homing to the gut: attraction, adhesion, and commitment. Immunol. Rev. (2005) 206:100-113. (Pubitemid 41105165)
103. YACYSHYN BR, CHEY WY, GOFF J et al.: Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohns disease. Gut (2002) 51(1):30-36. (Pubitemid 34717740)
104. SCHREIBER S, NIKOLAUS S, MALCHOW H et al.: Absence of efficacy of subcutaneous antisense ICAM-1 treatment of chronic active Crohns disease. Gastroenterology (2001) 120(6):1339-1346. (Pubitemid 32322307)
105. VAN DEVENTER SJ, TAMI JA, WEDEL MK: A randomised, controlled, double blind, escalating dose study of alicaforsen enema in active ulcerative colitis. Gut (2004) 53(11):1646-1651. (Pubitemid 39434109)
106. MAERTEN P, LIU ZCEUPPENS JL: Targeting of costimulatory molecules as a therapeutic approach in inflammatory bowel disease. Biodrugs (2003) 17(6):395-411. (Pubitemid 37500756)
107. KASRAN A, BOON L, WORTEL CH et al.: Safety and tolerability of antagonist anti-human CD40 Mab ch5D12 in patients with moderate to severe Crohns disease. Aliment. Pharmacol. Ther. (2005) 22(2):111-122. (Pubitemid 41039699)
108. FELL JM, WALKER-SMITH JA, SPENCER J, MACDONALD TT: The distribution of dividing T cells throughout the intestinal wall in inflammatory bowel disease (IBD). Clin. Exp. Immunol. (1996) 104(2):280-285. (Pubitemid 26135443)
109. THEISS AL, FRUCHTMAN S, LUND PK: Growth factors in inflammatory bowel disease: the actions and interactions of growth hormone and insulin-like growth factor-I. Inflamm. Bowel Dis. (2004) 10(6):871-880. (Pubitemid 39545231)
110. KONTUREK PC, BRZOZOWSKI T, DUDA A et al.: Epidermal growth factor and prostaglandin E2 accelerate mucosal recovery from stress-induced gastric lesions via inhibition of apoptosis. J. Physiol. Paris (2001) 95(1-6):361-367. (Pubitemid 33020261)
111. MIETTINEN PJ, BERGER JE, MENESES J: Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature (1995) 376(6538):337-341.
112. PROCACCINO F, REINSHAGEN M, HOFFMANN P et al.: Protective effect of epidermal growth factor in an experimental model of colitis in rats. Gastroenterology (1994) 107(1):12-17. (Pubitemid 24195340)
113. SINHA A, NIGHTINGALE J, WEST KP, BERLANGA-ACOSTA J, PLAYFORD RJ: Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. N. Engl. J. Med. (2003) 349(4):350-357. (Pubitemid 36886241)
114. KARA E, SUNGURTEKIN H, SUNGURTEKIN U, ALKANAT M, ILKGUL O: The effect of recombinant human growth hormone (rhGH) on trinitrobenzene sulfonic acid-induced colitis in rats: an experimental study. Inflamm. Bowel Dis. (2004) 10(2):112-115. (Pubitemid 38332170)
115. HAN X, SOSNOWSKA D, BONKOWSKI EL, DENSON LA: Growth hormone inhibits signal transducer and activator of transcription 3 activation and reduces disease activity in murine colitis. Gastroenterology (2005) 129(1):185-203. (Pubitemid 41002054)
116. WILLIAMS KL, FULLER CR, DIELEMAN LA et al.: Enhanced survival and mucosal repair after dextran sodium sulfate-induced colitis in transgenic mice that overexpress growth hormone. Effect of growth hormone on the inflammatory activity of experimental colitis in rats. Gastroenterology (2001) 120(4):925-937. (Pubitemid 32193189)
117. SLONIM AE, BULONE L, DAMORE MB: A preliminary study of growth hormone therapy for Crohns disease. N. Engl. J. Med. (2000) 342(22):1633-1637. (Pubitemid 30341532)
118. ZEEH JM, PROCACCINO F, HOFFMANN P et al.: Keratinocyte growth factor ameliorates mucosal injury in an experimental model of colitis in rats. Gastroenterology (1996) 110(4):1077-1083. (Pubitemid 26113747)
119. GREENWOOD-VAN MEERVELD B, VENKOVA K, CONNOLLY K: Efficacy of repifermin (keratinocyte growth factor-2) against abnormalities in gastrointestinal mucosal transport in a murine model of colitis. J. Pharm. Pharmacol. (2003) 55(1):67-75. (Pubitemid 36142083)
120. SANDBORN WJ, SANDS BE, WOLF DC et al.: Repifermin (keratinocyte growth factor-2) for the treatment of active ulcerative colitis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Aliment. Pharmacol. Ther. (2003) 17(11):1355-1364. (Pubitemid 36774142)
121. SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G: Thalidomide selectively inhibits tumor necrosis factor á production by stimulated human monocytes. J. Exp. Med. (1991) 173(3):699-703.
122. BAUDITZ J, WEDEL S, LOCHS H: Thalidomide reduces tumour necrosis factor á and interleukin 12 production in patients with chronic active Crohns disease. Gut (2002) 50(2):196-200 (Pubitemid 34087931)
123. MAZZON E, MUIA C, DI PAOLA R, GENOVESE T, DE SARRO A, CUZZOCREA S: Thalidomide treatment reduces colon injury induced by experimental colitis. Shock (2005) 23(6):556-564. (Pubitemid 40677430)
124. SABATE JM, VILLAREJO J, LEMANN M, BONNET J, ALLEZ M, MODIGLIANI R: An open-label study of thalidomide for maintenance therapy in responders to infliximab in chronically active and fistulizing refractory Crohns disease. Aliment. Pharmacol. Ther. (2002) 16(6):1117-1124. (Pubitemid 34680754)
125. HOMMES D, VAN DEN BLINK B, PLASSE T et al.: Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohns disease. Gastroenterology (2002) 122(1):7-14. (Pubitemid 34049188)
126. HOLLENBACH E, VIETH M, ROESSNER A, NEUMANN M, MALFERTHEINER P, NAUMANN M: Inhibition of RICK/nuclear factor-B and p38 signaling attenuates the inflammatory response in a murine model of Crohns disease. J. Biol. Chem. (2005) 280(15):14981-14988. (Pubitemid 40562850)
127. PAPADAKIS KA, PREHN J, MORENO ST et al.: CCR9-positive lymphocytes and thymus-expressed chemokine distinguish small bowel from colonic Crohns disease. Gastroenterology (2001) 121(2):246-254. (Pubitemid 32729371)
128. COMINELLI F: Cytokine-based therapies for Crohns disease-new paradigms. N. Engl. J. Med. (2004) 351(20):2045-2048. (Pubitemid 39482497)